More detailed studies including proteomics are needed to solidify the significance of KIF2C as a diagnostic/prognostic marker for cancer patients, as clearly proposed for breast cancer, NSCLC and HCC (Figure 3(A–C)). This evidence concerns the gene KIF2C and non-small cell lung carcinoma.